Tvardi Therapeutics Inc宣布,其核心候选药物Tti-101在肝细胞癌(HCC)患者中进行的二期临床试验,目前进展顺利。公司确认,该项研究的关键顶线数据仍按计划将于2026年下半年揭晓。
这一重要里程碑的推进,标志着Tvardi公司在开发针对STAT3信号通路的新型口服小分子抑制剂方面取得了持续进展。Tti-101作为一种潜在的突破性疗法,旨在直接靶向STAT3,该靶点在多种实体瘤的生长和存活中扮演着关键角色。
Tvardi Therapeutics Inc宣布,其核心候选药物Tti-101在肝细胞癌(HCC)患者中进行的二期临床试验,目前进展顺利。公司确认,该项研究的关键顶线数据仍按计划将于2026年下半年揭晓。
这一重要里程碑的推进,标志着Tvardi公司在开发针对STAT3信号通路的新型口服小分子抑制剂方面取得了持续进展。Tti-101作为一种潜在的突破性疗法,旨在直接靶向STAT3,该靶点在多种实体瘤的生长和存活中扮演着关键角色。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.